IP Library Granted Patent US 10,544,192
Granted Patent B2
US 10,544,192 · App. 15/623,723 · Granted Jan 28, 2020

Chimpanzee clade E adenovirus nucleic acid-and amino acid-sequences, vectors containing same, and uses thereof

Inventors: Stefano Colloca (Rome, IT); Alfredo Nicosia (Rome, IT); Riccardo Cortese, Sr. (Rome, IT); Virginia Ammendola (S. Guisepe Vesuviano, IT); Maria Ambrosio (Terzigno, IT)
Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
C07K14/005A61K39/12A61K39/235C12N7/00C12N15/86A61K39/0011A61K48/00A61K2039/525A61K2039/5256A61K2039/545C12N2710/10321C12N2710/10322C12N2710/10334C12N2710/10343C12N2710/16634C12N2740/16134C12N2770/24234
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,544,192
App. No.
15/623,723
Granted
Jan 28, 2020
Kind
B2
Abstract

The present invention relates to novel adenovirus strains with an improved seroprevalence. In one aspect, the present invention relates to isolated polypeptides of adenoviral capsid proteins such as hexon, penton and fiber protein and fragments thereof and polynucleotides encoding the same. Also provided is a vector comprising the isolated polynucleotide according to the invention and adenoviruses comprising the isolated polynucleotides or polypeptides according to the invention and a pharmaceutical composition comprising said vector, adenovirus, polypeptide and/or polynucleotide. The invention also relates to the use of the isolated polypeptides, the isolated polypeptides, the vector, the adenoviruses and/or the pharmaceutical composition for the therapy or prophylaxis of a disease.

Claims (7)

1. A recombinant adenoviral vector encoding a heterologous hexon protein comprising a polynucleotide that encodes an adenoviral hexon protein, wherein the polynucleotide is selected from the group consisting of:

(a) a polynucleotide encoding a polypeptide having the amino acid sequence of SEQ ID NO: 16;

(b) a polynucleotide encoding a polypeptide having the amino acid sequence of SEQ ID NO: 16, wherein the polypeptide comprises a deletion, insertion or substitution of not more than 35 amino acid residues; and

(c) a polynucleotide encoding a polypeptide having an amino acid sequence which is at least 90% identical over its entire length to the amino acid sequence of SEQ ID NO: 16;

further comprising at least one of a polynucleotide encoding a polypeptide having the amino acid sequence of SEQ ID NO: 22 and a polynucleotide encoding a polypeptide having the amino acid sequence of SEQ ID NO: 28.

2. The recombinant adenoviral vector of claim 1 wherein the vector comprises a polynucleotide encoding a polypeptide having the amino acid sequence of SEQ ID NO: 16, polynucleotide encoding a polypeptide having the amino acid sequence of SEQ ID NO: 22 and a polynucleotide encoding a polypeptide having the amino acid sequence of SEQ ID NO: 28.

3. The recombinant adenoviral vector of claim 2 , wherein the E4 region of the vector comprises ORF6 from human adenovirus.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 10, 2019
From: COLLOCA, STEFANO; NICOSIA, ALFREDO; CORTESE, RICCARDO; AMMENDOLA, VIRGINIA; AMBROSIO, MARIA
To: OKAIROS AG
Reel/Frame 051232/0420 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 10, 2019
From: OKAIROS AG
To: GLAXOSMITHKLINE BIOLOGICALS SA
Reel/Frame 051232/0639 →
Priority Claims (1)
WO PCT/EP2009/000672 · Feb 2, 2009 · international
Continuity (5)
Division 13147193
Provisional Application 61266342 · Dec 3, 2009
Provisional Application 61174852 · May 1, 2009
Provisional Application 61172624 · Apr 24, 2009
Related Publication 20180057540A1 · Mar 1, 2018
Cited By (4)
US 12,281,324 US 12,365,878 US 12,514,887 US 12,589,128